--- title: "Aurinia Pharmaceuticals (AUPH) Launches PRESERVE Study, Is A 5% Undervalued View Enough?" type: "News" locale: "en" url: "https://longbridge.com/en/news/292032366.md" description: "Aurinia Pharmaceuticals launched the PRESERVE Phase 4 study for its lupus nephritis drug LUPKYNIS. Despite a strong 1-year shareholder return of 113.70%, analyst narratives suggest the stock is only slightly undervalued, with a fair value estimate of $17.00 against a recent close of $16.22. The investment case hinges on revenue expansion and pipeline potential, though risks include heavy dependence on LUPKYNIS and uncertain R&D outcomes." datetime: "2026-07-08T07:59:58.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/292032366.md) - [en](https://longbridge.com/en/news/292032366.md) - [zh-HK](https://longbridge.com/zh-HK/news/292032366.md) generator: "portal-rs" --- # Aurinia Pharmaceuticals (AUPH) Launches PRESERVE Study, Is A 5% Undervalued View Enough? Aurinia Pharmaceuticals (AUPH) is drawing fresh attention after announcing PRESERVE, a Phase 4 multicenter study testing its oral lupus nephritis drug LUPKYNIS alongside three established immune therapies. See our latest analysis for Aurinia Pharmaceuticals. The PRESERVE announcement comes after a strong period for Aurinia Pharmaceuticals, with a 1 year total shareholder return of 113.70% and a more moderate 5.67% year to date share price return. This suggests momentum that investors are now reassessing alongside new clinical data. If developments around LUPKYNIS have your attention, it could be a useful time to see what else is emerging in healthcare related AI by checking out 40 healthcare AI stocks After Aurinia Pharmaceuticals’ sharp 1 year share price move and the latest PRESERVE study news, the practical question is whether you lean into the current set up or hold off and wait for a cheaper entry. ## Most Popular Narrative: 5% Undervalued The most followed narrative currently pegs Aurinia Pharmaceuticals’ fair value at $17.00 per share, only slightly above the last close at $16.22, so the focus shifts to what is built into that view. > *A biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs.* *Read the complete narrative.* Read the complete narrative. Want to see what is really backing that $17.00 fair value? The narrative leans heavily on revenue expansion, margin compression and a future earnings multiple that differs from today. Curious which assumptions do the heavy lifting and how they tie back to Aurinia’s current lupus nephritis franchise and pipeline potential? The full story sits inside that narrative. **Result: Fair Value of $17.00 (UNDERVALUED)** Have a read of the narrative in full and understand what's behind the forecasts. However, the Aurinia Pharmaceuticals story still hinges on its heavy dependence on LUPKYNIS, as well as uncertain outcomes related to future R&D spending and regulatory decisions for the pipeline. Find out about the key risks to this Aurinia Pharmaceuticals narrative. ## Next Steps If this Aurinia Pharmaceuticals snapshot feels mixed, with clear risks on one side and meaningful potential on the other, move quickly and weigh the full picture by reviewing the 3 key rewards and 2 important warning signs. ## Looking for more investment ideas beyond Aurinia Pharmaceuticals? If Aurinia Pharmaceuticals has sharpened your focus, do not stop here; broaden your watchlist with other stock ideas that could suit different roles in your portfolio. - Target potential mispricings by scanning for companies that combine quality fundamentals with attractive valuations through the 45 high quality undervalued stocks. - Strengthen your income stream by finding companies with higher yields and resilient payouts using the 9 dividend fortresses. - Prioritize resilience by focusing on companies with healthier balance sheets and solid fundamentals via the solid balance sheet and fundamentals stocks screener (47 results). *This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.* ### **New:** Manage All Your Stock Portfolios in One Place We've created the **ultimate portfolio companion** for stock investors, **and it's free.** • Connect an unlimited number of Portfolios and see your total in one currency • Be alerted to new Warning Signs or Risks via email or mobile • Track the Fair Value of your stocks Try a Demo Portfolio for Free ### Related Stocks - [AUPH.US](https://longbridge.com/en/quote/AUPH.US.md) ## Related News & Research - [Deutsche Bank AG Makes New $3.56 Million Investment in Aurinia Pharmaceuticals Inc $AUPH](https://longbridge.com/en/news/297141671.md) - [Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug](https://longbridge.com/en/news/296500759.md) - [ANI Pharma CEO Nikhil Lalwani disposes of 5,400 common shares worth $401,220](https://longbridge.com/en/news/297093829.md) - [MrBeast, Snapchat, AI and more: Pharma marketing’s pulse check](https://longbridge.com/en/news/297343211.md) - [BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines | ONC Stock News](https://longbridge.com/en/news/297552849.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**